Kalaris Therapeutics, Inc. (KLRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $34.76M
Last updated: Nov 17, 2026 at 4:10 PM ET
Kalaris Therapeutics, Inc. (KLRS) Stock Chart
Kalaris Therapeutics (KLRS) has a latest price of $1.43 on Nov 17, 2026, 88.0% below its 52-week high of $11.88. Its price fell 73.8% over the past 12 months. The month-end price fell 99.6% over the 5 years through Oct 2026, a compound annual decline of 67.4%.
Price Chart
From Jul 2020 to Oct 2026, its highest month-end close was $910.57 in Nov 2020 and its lowest $2.03 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart KLRS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for KLRS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 65.7%, and over 6 months it fell 69.6%. The month-end price fell 94.1% over the 3 years through Oct 2026, a compound annual decline of 61.1%.
| Period | Change |
|---|---|
| 1 month | -25.1% |
| 3 months | -65.7% |
| 6 months | -69.6% |
| 12 months | -73.8% |
| 12 months, with dividends | -73.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -94.1% | -61.1% |
| 5 years | -99.6% | -67.4% |
Price by Year
Its best calendar year was 2025, when the price fell 12.6%, and its weakest was 2023, when it fell 86.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.03 | -75.9% |
| 2025 | $8.44 | -12.6% |
| 2024 | $9.66 | -38.2% |
| 2023 | $15.63 | -86.7% |
| 2022 | $117.93 | -60.4% |
| 2021 | $297.47 | -66.3% |
Trading Range
The price is 41.6% below its 50-day average of $2.45 and 71.1% below its 200-day average of $4.95.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.43 | |
| 52-week high | $11.88 | -88.0% |
| 52-week low | $1.41 | +1.4% |
| 50-day average | $2.45 | -41.6% |
| 200-day average | $4.95 | -71.1% |
Price Risk
Over 3 years, its largest fall from a peak was 97.4%.
| Measure | Value |
|---|---|
| 1-year beta | 0.55 |
| Largest fall, 1 year | -87.0% |
| Largest fall, 3 years | -97.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About KLRS
What is KLRS's 1-year price change?
Kalaris Therapeutics's price fell 73.8% over the past 12 months. With dividends included, the 12-month total return was -73.8%.
What is KLRS's 5-year price change?
Kalaris Therapeutics's month-end price fell 99.6% over the 5 years through Oct 2026, a compound annual decline of 67.4%. These figures leave out dividends.
What is KLRS's 52-week high and low?
Kalaris Therapeutics's 52-week high is $11.88 and its 52-week low is $1.41. Its latest price of $1.43 on Nov 17, 2026 is 88.0% below the high.
What is KLRS's beta?
Kalaris Therapeutics's 1-year beta against the S&P 500 is 0.55, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 87.0%.
Is the KLRS chart free?
Yes. Advanced Charting for KLRS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
KLRS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors